Mastek is a good example of Daljeet’s foresight and dogged perseverance. In July 2014, when Mastek was languishing at Rs. 190, Daljeet recommended a buy on the basis that there is a possibility of value unlocking by way of divestment/ listing of U. S. Insurance business separately.
This prediction came true in September 2014 when Mastek announced the demerger of the insurance products and services business to Majesco Ltd. Though the price surged to Rs. 272, Daljeet maintained a buy with the promise of a target price of Rs. 550.
Today, there was more good news in store for the shareholders of Mastek. The management announced that Majesco Inc (100% subsidiary of Mastek Ltd) has acquired US based Agile Technologies (Agile), an insurance-industry-focused IT consulting firm with revenues of over $9 mn. Agile services has over 20 customers with a high quality talent pool of over 50 insurance technology professionals.
This news sent Mastek spiralling up 20% to touch Rs. 325, giving a gain of 68% since Daljeet’s recommendation in July 2014.
Daljeet has now issued an update report stating that the corporate action is likely to enhance the overall valuation of the company. He has advised a buy with the target price of Rs.550 per share.
Another recommended stock of Daljeet Kohli which has come good is OnMobile Global. I wrote about it a couple of days ago. The stock is looking quite strong at present and has nearly doubled over the past one month.
However, Sharon Bio-Medicine spoilt the party by plunging 20% today. The stock appears to have completely lost its mojo. After surging like a rocket a few months ago, the stock appears to have lost the confidence of some heavy duty investor(s). Daljeet issued an update report a few days ago stating that the steep fall in Sharon’s price has made the stock more attractive. He has advised a buy with a target price of Rs. 140. We will have to see what caused today’s crash and wait for a further update from Daljeet on the future course of action.
yes – along with the good news, its good that you write about the losses that some of these recommendations have faced. Even good old Dolly Khanna must be stuck with Selan exploration.
plz explain reasons of fall of sharon bio and future scope.
waiting for update from daljeet ji
Kabhi Khushi , Kabhi Gham. Daljeet in dilemma whether to celebrate or not.
If there is any good fundamental strength in SHARON it should be visible now only after couple of weeks. Let the fight between Bulls and Bears get over in this stock.
Stock if drops below 20 it would be worth trying luck is question mark for me
I’m sure, there would be a great opportunity in Sharon Bio for those who will manage to enter AROUND THE BOTTOM…. But Daljeet would not care to give that level to the already hurt people..And Only he can help here…. If he could work out with the management with some pressure, to find out the pledged share and their non-payment-plan of debt to banks resulting in more selling by banks…. It is possible to find out the bottom….
I was buying Sintex from 160..on suggestion from EM(equity-master). when it started falling due to forex losses, EM suggested to hold around 60 and not buy anymore (what a recommnedation!) but I bought at every 50% fall with double volumes.. then it went to 17 due to pledge share selling+global sell-off pressure ..I kept buying becoz I was double convinced about the company future which happened due to – Mangement came out in media and clarified/gave the details of present and future. Finally, I sold it with 90% profit.
my message is – Kohli should confirm us that co will definitely do better/(much better) in future, so that
we keep buying in LOW quantity so that we can buy more if falls furher 40-50 %
Accumulating during pledged share-sell is Trying to gain from Tsunami… U can die if co has big operational/business problems OR U dont have more fund to buy @ next 50% decline.
Basically if the co/business is good, Its a great opportunity. But DALJEET has to confirm this to us that Its a great opportunity.